Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

SAR-153192 suppresses tumor growth in vivo and continues evaluation in phase I trial

Nov. 29, 2010

New oxalato complexes of platinum disclosed for treatment of cancer

Nov. 26, 2010

First-in-human data presented on RO-5126766 in advanced/metastatic solid tumors

Nov. 26, 2010

Tragara advances multikinase inhibitor SB-1317 to phase I trial

Nov. 25, 2010

Boehringer Ingelheim patents novel PI3K inhibitors

Nov. 25, 2010

Roche claims new inhibitors of Mdm2-p53 interaction

Nov. 25, 2010

In vivo antitumor effects of BIIB-024 support evaluation in phase I trials in melanoma/solid tumors

Nov. 25, 2010

Provectus updates compassionate use program for anticancer candidate PV-10

Nov. 25, 2010

First-in-human data disclosed on dual PI3K/mTOR inhibitors PF-05212384 and PF-04691502

Nov. 24, 2010

Boehringer Ingelheim describes novel mTOR inhibitors

Nov. 24, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...